Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
FGEN FibroGen
Post Mkt Price
Do not show
Hide blank lines
Total revenue
22.34% 29.81M 58.28% 60.83M 33.46% 235.31M -74.55% 16.54M
Operating revenue
56.31% 38.08M 58.28% 60.83M 33.46% 235.31M -74.55% 16.54M
Cost of revenue
121.22% 6.81M 24.61% 4.24M 45.12% 12.87M 19.5% 3.13M
Gross profit
8.04% 23M 61.55% 56.59M 32.84% 222.44M -78.49% 13.42M
Operating expense
-34.75% 101.22M 13.4% 119.58M 42.2% 510.97M 23.49% 148.66M
Selling and administrative expenses
-7.05% 30.26M -0.7% 30.56M 16.46% 123.93M -17.78% 34.74M
Research and development costs
-42.1% 70.96M 19.21% 89.02M 53.03% 387.04M 45.8% 113.92M
Operating profit
41.55% -78.22M 10.56% -62.99M -50.37% -288.53M -133.18% -135.24M
Net non-operating interest income expense
804.46% 5.06M 16.37% -419K -168.33% -2.15M 440.15% 932K
Non-operating interest income
-- 5.2M -- -- -- -- 294.7% 1.04M
Non-operating interest expense
-80.36% 141K -16.37% 419K -10.37% 2.15M -79.55% 110K
Other net income (expense)
Income before tax
45.62% -73.17M 11.16% -63.41M -53.86% -290.68M -129.73% -134.31M
Income tax
866.67% 23K -15.67% 113K -3.61% 347K -34.5% 112K
Earnings from equity interest net of tax
0.53% 565K 233.33% 320K -- 1.01M -- 342K
Net income
45.8% -72.62M 11.92% -63.21M -53.22% -290.02M -128.67% -134.08M
Net income continuous Operations
45.8% -72.62M 11.92% -63.21M -53.22% -290.02M -128.67% -134.08M
Minority interest income
Net income attributable to the parent company
45.8% -72.62M 11.92% -63.21M -53.22% -290.02M -128.67% -134.08M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
45.8% -72.62M 11.92% -63.21M -53.22% -290.02M -128.67% -134.08M
Basic earnings per share
46.21% -0.78 12.82% -0.68 -48.82% -3.14 -126.56% -1.45
Diluted earnings per share
46.21% -0.78 12.82% -0.68 -48.82% -3.14 -126.56% -1.45
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Hot List
SymbolLatest price%Chg